Ramucirumab

Recent Findings on ramucirumab

• Advanced gastric and gastroesophageal junction cancer: A 2026 matching-adjusted indirect comparison evaluated fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. The publication characterized ramucirumab as an anti-VEGFR2 antibody and referenced efficacy demonstrated in the RAINBOW-Asia trial 42583940Aug. This work extends the literature theme of ramucirumab plus paclitaxel in advanced gastric cancer by placing ramucirumab in comparative context with fruquintinib, another angiogenesis-directed treatment.

• A Japanese clinical oncology study examined how prior nivolumab affected outcomes from taxane plus ramucirumab in advanced gastric cancer. The study addressed HER2-negative disease in a treatment environment where combination chemotherapy with an immune checkpoint inhibitor had become a standard first-line approach, while the influence of that prior immunotherapy on subsequent ramucirumab-containing treatment remained uncertain 42247598Jun. Thus, the study focused on treatment sequencing between nivolumab-based therapy and taxane–ramucirumab therapy rather than on ramucirumab as an isolated treatment.

• A case report described a patient with HER2-negative esophagogastric junction cancer who received ramucirumab plus paclitaxel after nivolumab-based chemotherapy. The patient had a marked radiological and metabolic response, proceeded to conversion-intent surgery, and had a pathological complete response in the resected specimen 42541665Aug. This report specifically links ramucirumab plus paclitaxel with post-immunotherapy treatment and surgical conversion in an individual case; it does not establish the frequency of this outcome in a broader population.

• Advanced NSCLC: A phase II study named DRUN investigated docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC. The publication described docetaxel–ramucirumab as a standard second-line treatment for advanced NSCLC and examined its use directly after immune-based treatment 42150483May. The study therefore extends the immunotherapy-sequencing theme from gastrointestinal cancers to lung cancer.

• A single-institution retrospective study evaluated docetaxel plus ramucirumab in advanced NSCLC patients with malignant pleural effusion or cerebral edema. Its rationale was that, although bevacizumab had shown efficacy in these settings, comparatively limited research had evaluated ramucirumab as an angiogenesis inhibitor 42067397May. The study addressed possible disease-specific supportive or anticancer applications of ramucirumab in patients with pleural and intracranial complications, but the provided context does not report quantitative efficacy or safety results.

• Metastatic colorectal cancer: A retrospective comparison assessed second-line FOLFIRI plus ramucirumab according to prior biologic exposure. Patients were categorized according to prior bevacizumab or prior anti-EGFR therapy, and the study evaluated clinical outcomes in metastatic colorectal cancer after oxaliplatin-based treatment 42360560Jun. The publication described ramucirumab plus FOLFIRI as an established second-line option and focused on whether the preceding biologic strategy influenced subsequent treatment outcomes.

• A multicenter retrospective study likewise evaluated fluorouracil, leucovorin, and irinotecan plus ramucirumab according to the preceding first-line regimen in metastatic colorectal cancer. The treatment was examined after different first-line approaches, including bevacizumab-based chemotherapy, and was characterized as a well-established second-line regimen 42018104Apr. Together with the prior study, this work extends the bevacizumab-in-metastatic-CRC theme by examining how prior biologic exposure may relate to outcomes with a subsequent VEGFR2-directed regimen.

• A randomized phase II study, WJOG9216G (RECAST), compared FOLFIRI plus ramucirumab with FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer. The study was motivated by the lack of established knowledge regarding ramucirumab combined with either FOLFIRI or the more intensive FOLFOXIRI regimen in the first-line setting 41880871Mar. It therefore explores a treatment context beyond the established second-line use of ramucirumab plus FOLFIRI and evaluates whether adding oxaliplatin to the chemotherapy backbone changes clinical outcomes.